Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Galera Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GRTX
Nasdaq
8731
https://www.galeratx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Galera Therapeutics Inc
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
- Mar 10th, 2023 12:00 pm
These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
- Mar 8th, 2023 2:53 pm
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
- Mar 8th, 2023 12:00 pm
Galera Therapeutics expects to raise $30M from direct stock offering
- Feb 15th, 2023 5:43 pm
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
- Feb 15th, 2023 1:45 pm
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
- Feb 15th, 2023 1:00 pm
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
- Feb 5th, 2023 12:35 pm
Malvern-based Galera shares rise on FDA filing for lead cancer therapy drug
- Dec 12th, 2022 4:37 pm
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
- Dec 12th, 2022 12:00 pm
Galera to Present at Piper Sandler Annual Healthcare Conference
- Nov 22nd, 2022 12:00 pm
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
- Nov 9th, 2022 12:00 pm
One Galera Therapeutics, Inc. (NASDAQ:GRTX) insider upped their stake by 50% in the previous year
- Nov 7th, 2022 3:08 pm
Galera Therapeutics' Avasopasem Reduces Chemo-Related Kidney Disease By 50% Versus Placebo At One-Year
- Oct 26th, 2022 7:16 pm
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
- Oct 26th, 2022 5:40 pm
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
- Sep 26th, 2022 11:00 am
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- Sep 6th, 2022 11:00 am
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
- Sep 1st, 2022 11:00 am
Here's Why Galera Therapeutics (NASDAQ:GRTX) Must Use Its Cash Wisely
- Aug 29th, 2022 10:47 am
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
- Aug 9th, 2022 11:00 am
Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation
- Jun 29th, 2022 4:05 pm
Scroll